FDA Sees Challenge In Distinguishing Lung Cancer Symptoms From Drug Side Effects
Executive Summary
At the third patient-focused drug development meeting under PDUFA V, FDA staff urged patients to try to differentiate between symptoms caused by the underlying disease and those resulting from treatment, an important distinction when it comes to assessing the efficacy and safety of new drugs.
You may also be interested in...
Fibromyalgia Patient Meeting Shines Light On Lesser Known Symptoms
While pain and fatigue are well-recognized symptoms of fibromyalgia, patients testifying at the PDUFA V disease area meeting gave FDA drug review staff insight into other health effects, such as visual disturbances.
Patient-Reported Outcomes Tools Should Be Symptom Specific, FDA Says
Agency favors symptom-focused assessments over global quality-of-life evaluations when considering whether the data can support a drug labeling claim for use in treating pediatric cancer. Measures used for EU reimbursement considerations are usually not sufficient for FDA labeling claims, official cautions.
FDA Asks Narcolepsy Patients How Symptoms Change Over Time
Agency plans a half-day meeting Sept. 24 on narcolepsy symptom burden and current treatment options, part of its patient-focused drug development initiative under PDUFA V.